Press Releases

Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes

by

Surface engineering of exosomes for improved tissue-targeting published by Evox co-founder Oxford, UK, May 20, 2024 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced the peer reviewed publication of Evox-funded research in Nature Biomedical Engineering, a high-impact journal. In this paper, entitled “Targeted Therapy by Antibody Displaying Extracellular Vesicles”, Wiklander et … Read more

Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive Officer

by

Oxford, U.K. April 29, 2024 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer (CEO) of the Company and will be appointed to its Board of Directors. Following more than six years with the … Read more

Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platform

by

Novel scaffold proteins for improved drug loading published by Evox co-founder Oxford, UK, August 9, 2023 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced the publication in Nature Communications of Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes. The publication can be … Read more

Evox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease

by

The agreement aims to tackle long-standing challenges in cardiovascular disease Oxford, UK, August 4, 2023 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY. The collaboration will work on developing … Read more

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

by

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors Oxford, U.K. June 20, 2023 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ … Read more

Evox Therapeutics Granted Key US Exosome Purification Patent to Further Expand Its Leading Patent Portfolio

by

Newly issued US patent covers key step in the exosome manufacturing process Oxford, United Kingdom, May 17, 2023 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted another US patent adding to its growing manufacturing IP portfolio. Evox has been granted US Patent … Read more

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics

by

Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the International Society for Extracellular Vesicles (ISEV) OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: … Read more